FBRX – Forte Biosciences Inc
Forte Biosciences, Inc.FBRX
$30.60Name : Forte Biosciences, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $599,625,472.00
EPSttm : -4.71
Forte Biosciences, Inc.
$30.60
12.80%$4.49
FBRX — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
7.39
Margin Of Safety %
Put/Call OI Ratio
0.34
EPS Next Q Diff
0.4
EPS Last/This Y
0.37
EPS This/Next Y
0.02
Price
30.72
Target Price
63.75
Analyst Recom
1
Performance Q
28.14
Upside
-322.6%
Beta
3.31
Ticker: FBRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-17 | FBRX | 26.42 | 0.21 | 0.00 | 375 |
| 2026-03-18 | FBRX | 25 | 0.05 | 999.99 | 1430 |
| 2026-03-20 | FBRX | 23.23 | 0.05 | 0.00 | 1432 |
| 2026-03-25 | FBRX | 26.35 | 0.05 | 999.99 | 1418 |
| 2026-03-26 | FBRX | 27.11 | 0.12 | 0.00 | 1518 |
| 2026-03-27 | FBRX | 25.65 | 0.12 | 999.99 | 1528 |
| 2026-03-30 | FBRX | 26.3 | 0.12 | 999.99 | 1528 |
| 2026-03-31 | FBRX | 25.93 | 0.12 | 999.99 | 1528 |
| 2026-04-01 | FBRX | 25.01 | 0.20 | 0.00 | 1628 |
| 2026-04-06 | FBRX | 26.34 | 0.20 | 0.00 | 1630 |
| 2026-04-07 | FBRX | 26.28 | 0.20 | 0.00 | 1630 |
| 2026-04-08 | FBRX | 26.24 | 0.20 | 999.99 | 1630 |
| 2026-04-09 | FBRX | 33.65 | 0.20 | 9.60 | 1632 |
| 2026-04-10 | FBRX | 34.09 | 0.32 | 3.95 | 1813 |
| 2026-04-13 | FBRX | 30.81 | 0.34 | 39.00 | 1868 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-17 | FBRX | 26.27 | - | - | -4.32 |
| 2026-03-18 | FBRX | 24.88 | - | - | -4.32 |
| 2026-03-19 | FBRX | 24.59 | - | - | -4.32 |
| 2026-03-20 | FBRX | 22.88 | - | - | -4.32 |
| 2026-03-23 | FBRX | 25.65 | - | - | -4.32 |
| 2026-03-24 | FBRX | 25.57 | - | - | -4.32 |
| 2026-03-25 | FBRX | 26.59 | - | - | -4.32 |
| 2026-03-26 | FBRX | 27.23 | - | - | -4.32 |
| 2026-03-27 | FBRX | 25.69 | - | - | -4.32 |
| 2026-03-30 | FBRX | 26.16 | - | - | -4.32 |
| 2026-03-31 | FBRX | 25.83 | - | - | -4.32 |
| 2026-04-01 | FBRX | 24.92 | - | - | -4.32 |
| 2026-04-02 | FBRX | 25.56 | - | - | -4.32 |
| 2026-04-06 | FBRX | 26.49 | 14.6 | - | -4.47 |
| 2026-04-07 | FBRX | 26.29 | 14.6 | - | -4.47 |
| 2026-04-08 | FBRX | 26.13 | 14.6 | - | -4.31 |
| 2026-04-09 | FBRX | 33.70 | 14.6 | - | -4.34 |
| 2026-04-10 | FBRX | 34.99 | 15.3 | - | -4.34 |
| 2026-04-13 | FBRX | 30.72 | 15.3 | - | -4.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-18 | FBRX | 0.59 | 5.42 | 6.54 |
| 2026-03-19 | FBRX | 0.59 | 5.42 | 6.54 |
| 2026-03-20 | FBRX | 0.59 | 5.42 | 6.54 |
| 2026-03-23 | FBRX | 0.59 | 5.43 | 6.54 |
| 2026-03-24 | FBRX | 0.59 | 5.43 | 6.54 |
| 2026-03-25 | FBRX | 0.59 | 5.43 | 6.68 |
| 2026-03-26 | FBRX | 0.59 | 5.43 | 6.68 |
| 2026-03-27 | FBRX | 0.59 | 5.43 | 6.68 |
| 2026-03-30 | FBRX | 0.59 | 5.45 | 6.68 |
| 2026-03-31 | FBRX | 0.59 | 5.45 | 6.68 |
| 2026-04-01 | FBRX | 0.59 | 5.45 | 6.68 |
| 2026-04-02 | FBRX | 0.59 | 5.45 | 6.68 |
| 2026-04-06 | FBRX | 0.54 | 4.84 | 6.03 |
| 2026-04-07 | FBRX | 0.54 | 4.84 | 6.03 |
| 2026-04-08 | FBRX | 0.54 | 4.84 | 6.03 |
| 2026-04-09 | FBRX | 0.54 | 4.84 | 6.03 |
| 2026-04-10 | FBRX | 0.54 | 4.84 | 6.03 |
| 2026-04-13 | FBRX | 0.54 | 2.83 | 7.39 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.45
Avg. EPS Est. Current Quarter
-1.18
Avg. EPS Est. Next Quarter
-1.05
Insider Transactions
0.54
Institutional Transactions
2.83
Beta
3.31
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
6
Growth Score
19
Sentiment Score
92
Actual DrawDown %
97.2
Max Drawdown 5-Year %
-99.6
Target Price
63.75
P/E
Forward P/E
PEG
P/S
P/B
6.5
P/Free Cash Flow
EPS
-5.24
Average EPS Est. Cur. Y
-4.34
EPS Next Y. (Est.)
-4.32
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.87
Return on Equity vs Sector %
-141.1
Return on Equity vs Industry %
-124.5
EPS 1 7Days Diff
-0.8
EPS 1 30Days Diff
-0.75
EBIT Estimation
◆
FBRX
Healthcare
$30.60
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
56.6
Range 1M
59.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
9.6%
EPS NY
1.9%
52W%
81.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+108.3% upside
Upside
+108.3%
Quality
6
Forte Biosciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 19
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
FBRX
Latest News
—
Caricamento notizie per FBRX…
stock quote shares FBRX – Forte Biosciences Inc Stock Price stock today
news today FBRX – Forte Biosciences Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FBRX – Forte Biosciences Inc yahoo finance google finance
stock history FBRX – Forte Biosciences Inc invest stock market
stock prices FBRX premarket after hours
ticker FBRX fair value insiders trading